Related Experiment Video
Updated: Jun 30, 2026
A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
Identification of minimal sequence for HIV-1 fusion inhibitors
Hiroki Nishikawa1, Shinya Oishi, Mizuno Fujita
1Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.
Abstract:
Emergence of multi-drug resistant HIV-1 is a serious problem for AIDS treatment. Recently, the virus-cell membrane fusion process has been identified as a promising target for the development of novel drugs against these resistant variants. In this study, we identified a 29-residue peptide fusion inhibitor, SC29EK, which shows activity comparable to the previously reported inhibitor SC35EK. Some residues in SC29EK not required for interaction with virus gp41 heptad repeat 1 (HR1) were replaced with a non-proteinogenic amino acid, 2-aminoisobutyric acid (Aib), to stabilize the alpha-helix structure and to provide resistance to peptidases.
Insights
A new peptide, SC29EK, shows promise for treating multi-drug resistant HIV-1 by inhibiting virus-cell fusion. Modifications with 2-aminoisobutyric acid enhance its stability against degradation, aiding AIDS therapy.
Area of Science:
- Biochemistry
- Virology
- Drug Discovery
Background:
- Multi-drug resistant human immunodeficiency virus type 1 (HIV-1) poses a significant challenge to acquired immunodeficiency syndrome (AIDS) treatment.
- The virus-cell membrane fusion process is a critical step in HIV-1 infection and a potential target for novel therapeutics.
Purpose of the Study:
- To identify and characterize a novel peptide fusion inhibitor targeting multi-drug resistant HIV-1 variants.
- To enhance the stability and efficacy of peptide inhibitors through amino acid modification.
Main Methods:
- Identification and characterization of the 29-residue peptide fusion inhibitor SC29EK.
- Modification of SC29EK by replacing specific residues with 2-aminoisobutyric acid (Aib).
- Assessment of inhibitor activity and stability, including interaction with viral gp41 heptad repeat 1 (HR1) and resistance to peptidases.
Main Results:
- SC29EK demonstrated fusion inhibitory activity comparable to the established inhibitor SC35EK.
- The incorporation of Aib into SC29EK stabilized its alpha-helix structure.
- Modified SC29EK exhibited increased resistance to peptidase degradation.
Conclusions:
- SC29EK is a potent peptide fusion inhibitor effective against multi-drug resistant HIV-1.
- The use of Aib provides a strategy to enhance the pharmacokinetic properties of peptide inhibitors for improved AIDS therapy.
